An anti-mitotic product with potent anticancer activity
Aphios produces a natural paclitaxel from the needles or leaves of the American yew, Taxus media "hicksii," utilizing its patented SuperFluids™ CXP technology (US Patents). Aphios also produces paclitaxel from the needles or leaves of the wild Canadian yew, Taxus canadensis.
Paclitaxel has demonstrated a significant effectiveness against ovarian and breast cancers, and a number of other cancers in clinical trials.
Paclitaxel is an anti-mitotic agent that works by stabilizing microtubules and preventing unregulated cell mitosis or division.
Paclitaxel is also being used as an adjunct therapy with the new breed of genetically engineered drugs as exemplified with Genentech's Herceptin®. The adjunct use of paclitaxel significantly increased the therapeutic effectiveness of Herceptin®.
Paclitaxel has repeatedly demonstrated an additive or synergistic effect with other drugs. Paclitaxel and its relatives thus hold the promise to have widespread applicability to cancer and other non-tumorgenic diseases.